Fosun Pharma’s Surufatinib Injection New Indication Approved
December 9, 2024
Source: drugdu
90
On December 3, Fosun Pharma announced that its subsidiary, Hansoh Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization application of Hansou® (Surufatinib Injection) in combination with Pemetrexed and Carboplatin for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that is negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion.
https://finance.eastmoney.com/a/202412033257905182.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Baili Tianheng’s revenue is expected to increase by 932% January 30, 2025
- Promoting the “going out” of medicines, my country opens up the “next stop” of medicine centralized procurement for ASEAN January 30, 2025
- Application for registration and marketing authorization of quadrivalent influenza vaccine has been accepted January 30, 2025
- Fosun Pharma’s drug registration application for salbutamol hydrochloride has been accepted January 30, 2025
- encourage and support pharmaceutical operators to strengthen anti-monopoly compliance January 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
